| domain | established finding | quantitative/variant detail | evidence type and year | evidence limitation |
|---|---|---|---|---|
| Disease naming / identifiers | A rare Mendelian neurodevelopmental disorder caused by pathogenic THOC2 variation; retrieved evidence supports names such as **THOC2-related intellectual disability**, **THOC2-associated neurodevelopmental disorder**, and **X-linked intellectual disability due to THOC2**. Do **not** assert MONDO/OMIM IDs here because they were not established in the retrieved evidence. (pqac-00000020, pqac-00000021) | Core phenotype is intellectual disability with variable syndromic features; THOC2 is on chromosome X and encodes the largest TREX subunit. (pqac-00000011, pqac-00000020) | Human clinical cohorts/reports, 2015 and 2018; mechanistic disease framing, 2024. (pqac-00000018, pqac-00000021, pqac-00000011) | Naming is consistent across papers, but registry identifiers were not retrieved directly. |
| Inheritance | Established **X-linked** inheritance with affected hemizygous males in multigenerational families; also **de novo** disease in at least one affected female and additional de novo male cases. (pqac-00000018, pqac-00000021, pqac-00000022) | 2015 cohort: 4 multigenerational families, 20 affected individuals. 2018 expansion: 6 affected individuals from 5 unrelated families plus 1 affected female with de novo p.Tyr517Cys. (pqac-00000018, pqac-00000021, pqac-00000022) | Human pedigree/genomic evidence, 2015 and 2018. | Penetrance is not formally quantified; female manifestations appear uncommon and likely influenced by X-inactivation. |
| Sex effects / X-inactivation | Heterozygous mothers were usually clinically unaffected and showed highly skewed X-chromosome inactivation when tested. (pqac-00000017, pqac-00000022, pqac-00000027) | Reported XCI skewing included ~94%, 98:2%, and 99.9:0.1%. (pqac-00000022, pqac-00000024) | Human clinical/molecular evidence, 2018. | Small number of carrier females studied; cannot define full female penetrance spectrum. |
| Core phenotypes | Intellectual disability is the consistent core phenotype, often with speech/language impairment, hypotonia, gait disturbance, tremor, seizures/epileptic encephalopathy, growth abnormalities, and occasional behavioral/autism features. (pqac-00000018, pqac-00000015, pqac-00000017) | 2015: severity ranged from borderline to severe; speech delay, short stature, elevated BMI/truncal obesity in older males in 2/4 families, seizure disorders, tremors, gait disturbance. (pqac-00000018) 2018 established series: all 7 had at least moderate ID; 2/7 non-ambulatory, 3/7 non-verbal, 4/7 behavioral problems, 1/7 ASD, 4/7 infantile hypotonia, 2/7 tremor, 1/7 confirmed seizures, 1/7 suspected seizures, 3/7 low birth weight, 2/7 microcephaly, 2/7 short stature. (pqac-00000015) | Human clinical cohort data, 2015 and 2018. | Frequencies are from small cohorts and partly enriched for severe referrals; not population estimates. |
| Neuroimaging / neurologic findings | Brain imaging can be normal or show nonspecific structural abnormalities; cerebellar-type signs may occur even without major cerebellar MRI abnormalities. (pqac-00000017, pqac-00000018) | 2018: abnormal MRI in 2/5 tested—cortical gyral changes, corpus callosum hypoplasia, reduced brainstem volume, lateral ventricle dilatation, delayed myelination, periventricular white matter lesions; 3/5 were normal. (pqac-00000015) 2015: mild ventriculomegaly, gliosis, inferior cerebellar vermis dysplasia, cervical cord compression reported in a limited subset. (pqac-00000018) | Human imaging observations, 2015 and 2018. | Imaging numbers are very small; no disease-specific radiologic signature established. |
| Established pathogenic / likely pathogenic variants | Established disease-causing variants include multiple missense and splice-altering THOC2 variants that reduce protein stability or create C-terminal truncation. (pqac-00000023, pqac-00000022, pqac-00000025, pqac-00000027) | 2015 established missense variants: c.937C>T (p.Leu313Phe), c.1313T>C (p.Leu438Pro), c.2399T>C (p.Ile800Thr), c.3034T>C (p.Ser1012Pro). (pqac-00000023, pqac-00000026) 2018 established variants include p.Tyr517Cys, p.Thr696Ile, p.Gly713Asp, p.His1187Tyr, and splice variants c.4450-2A>G and c.3503+4A>C / p.Gly1168fs7*. (pqac-00000021, pqac-00000022, pqac-00000025) | Human genomic + functional evidence, 2015 and 2018. | Variant list is restricted to retrieved papers; no contemporaneous ClinVar aggregation was retrieved. |
| VUS / candidate variants | Additional rare missense THOC2 variants were reported as **variants of uncertain significance** rather than established causes. (pqac-00000019, pqac-00000029) | Reported VUS: p.Arg77Cys, p.Ser1108Leu, p.Arg1121Gly, p.Asn1261His. They were rare/conserved and in silico-predicted damaging but lacked sufficient functional confirmation. (pqac-00000019, pqac-00000029) | Human genomic interpretation, 2018. | These should not be treated as confirmed causal variants without stronger evidence. |
| Population frequency | Established pathogenic variants were absent from large reference datasets, supporting rarity. (pqac-00000023, pqac-00000024, pqac-00000029) | 2015 variants absent in >60,000 individuals from 1000 Genomes/ExAC; 2018 variants absent in gnomAD/ExAC per report. (pqac-00000023, pqac-00000024, pqac-00000029) | Human variant interpretation, 2015 and 2018. | Database versions were historical; current allele frequencies were not independently re-queried here. |
| Molecular mechanism | THOC2 dysfunction compromises TREX-associated RNA biology and, in the 2024 model, causes **R-loop accumulation → DNA damage → cell-cycle disruption / apoptosis → adverse neurodevelopment**. (pqac-00000011, pqac-00000012) | 2024 mouse/patient study showed RNase H-sensitive R-loop accumulation in Thoc2Δ/Y neural stem cells and patient fibroblasts; RNase H1 overexpression reduced R-loops and DNA damage (****p<0.0001). (pqac-00000008, pqac-00000009) | Mouse + patient-derived cell mechanistic study, 2024. | Mechanism is strongly supported in the hypomorphic mouse model and patient fibroblasts, but not yet proven for every human variant. |
| 2024 model-organism / cell findings | A hypomorphic **Thoc2Δ/Y** mouse recapitulated major syndrome features and linked them to impaired neurodevelopment. (pqac-00000011, pqac-00000010, pqac-00000014) | Smaller size/weight; reduced birth rate by ~33%; deficits in spatial learning, working memory, fine motor/sensorimotor tasks; reduced cortical ventricular zone, cortical plate, and corpus callosum thickness; 32% shorter primary axons; fewer mature dendritic spines; reduced electrophysiologic activity. (pqac-00000010, pqac-00000013, pqac-00000014) | Mouse model + primary neurons/NSCs, 2024. | A hypomorphic exon 37-38 deletion model may not reflect all missense/splice variants or full human natural history. |
| Diagnostics | Diagnosis has been made by family-based sequencing approaches and modern exome/genome sequencing, followed by segregation and functional RNA/protein studies when needed. (pqac-00000023, pqac-00000025, pqac-00000026, pqac-00000028) | 2015: X-chromosome exome sequencing plus linkage (combined LOD 8.1) in 4 families. (pqac-00000023) 2018: WES/WGS/trio exome with Sanger confirmation; cDNA PCR, RT-qPCR, western blotting, immunofluorescence, cycloheximide chase used for splice/protein effect resolution. (pqac-00000022, pqac-00000025, pqac-00000026, pqac-00000028) | Human diagnostic genomics, 2015 and 2018. | No disease-specific consensus testing guideline or biomarker was retrieved. |
| Treatment / management | No disease-modifying therapy, targeted therapy, or disease-specific clinical trial was identified in the retrieved evidence; management appears supportive and symptom-based. (pqac-00000015, pqac-00000018) | Isolated report: one male had growth-hormone deficiency treated with replacement therapy. Supportive needs are implied by nonverbal/nonambulatory status, seizures, behavioral issues, and developmental disability. (pqac-00000016, pqac-00000015) Clinical trials search retrieved no relevant THOC2-specific interventional trial. | Human case management observations, 2015/2018; trial search negative. | Supportive care details were not systematically reported; no treatment outcome series or guidelines were retrieved. |
| Epidemiology | THOC2-related intellectual disability is **ultra-rare**; no prevalence or incidence estimate was identified in retrieved sources. (pqac-00000018, pqac-00000021) | Evidence base consists of small family series and case reports: 20 affected individuals in 2015 families, plus 7 established additional cases in 2018; papers mention broader totals including previously reported individuals, but no population denominator. (pqac-00000018, pqac-00000020, pqac-00000021) | Human rare-disease literature, 2015 and 2018. | No registry-based epidemiology, sex ratio estimate, or geographic prevalence study was retrieved. |


*Table: This table compacts the strongest retrieved evidence on THOC2-related intellectual disability, including inheritance, core phenotypes, variant classes, 2024 mechanism data, diagnostics, and major gaps. It is designed for rapid knowledge-base curation while clearly separating established findings from limited or absent evidence.*